Cost-effectiveness of a male catch-up human papillomavirus vaccination program in the Netherlands.

Autor:	Simons JJM; Market Access Department, GSK, Van Ash van Wijckstraat 55H, 3811 Amersfoort, the Netherlands.; Department of Health Sciences, University of Groningen, University Medical Center, Hanzeplein 1, 9713 GZ Groningen, the Netherlands., Westra TA; Market Access Department, GSK, Van Ash van Wijckstraat 55H, 3811 Amersfoort, the Netherlands., Postma MJ; Department of Health Sciences, University of Groningen, University Medical Center, Hanzeplein 1, 9713 GZ Groningen, the Netherlands.; Unit of Pharmacotherapy, -Epidemiology & -Economics, University of Groningen, Groningen Research Institute of Pharmacy, A Deusinglaan 1, 9713 AV Groningen, the Netherlands.; Department of Economics, Econometrics & Finance, University of Groningen, Faculty of Economics & Business, P.O. Box 800, 9700 AV Groningen, the Netherlands.
Jazyk:	angličtina
Zdroj:	Preventive medicine reports [Prev Med Rep] 2022 Jun 27; Vol. 28, pp. 101872. Date of Electronic Publication: 2022 Jun 27 (Print Publication: 2022).
DOI:	10.1016/j.pmedr.2022.101872
Abstrakt:	In the Netherlands, the Health Council has advised that the human papillomavirus (HPV) vaccination should be offered to both boys and girls. Additionally, boys and men up to the age of 26 years should be included in a catch-up program. In this study, we examine the cost-effectiveness of this HPV catch-up program. We used a static Markov model to estimate the amount of cancers prevented and the incremental cost-effectiveness ratio (ICER) for different scenarios. Vaccinating men from 12 until the age of 26 years would result in an average of 48 cancer cases prevented in every cohort (an estimated total of 720 cases), with an average ICER of €32,256. We found that the catch-up vaccination program results in a relevant number prevented cases against an acceptable cost-effectiveness ratio. Policymakers should take these findings into account when evaluating a gender-neutral HPV vaccination program in the Netherlands. Competing Interests: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: J.J.M. Simons and T.A. Westra are employed by the GSK group of companies. T.A. Westra holds shares in the GSK group of companies. M.J. Postma declares outside of the submitted work grants and personal fees from MSD, the GSK group of companies, Pfizer, Boehringer Ingelheim, BioMerieux, Novavax, BMS, Astra Zeneca, Sanofi, Novartis, Ingress Health, Pharmerit and IQVIA. M.J. Postma declares outside of the submitted work to hold shares from Health-Ecore (20%) and from PAG Ltd (100%). M.J. Postma declares outside of the submitted work financial support from Asc Academics as an adviser for this company. J.J.M. Simons, T.A. Westra and M.J. Postma declare no other financial and non-financial relationships and activities. (© 2022 GlaxoSmithKline Biologicals S.A. Published by Elsevier Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu